Is PMS relief becoming a consumer wellness category? Bayer’s Midol in Motion campaign suggests so
PMS relief is moving beyond pain pills. Bayer’s Midol campaign ties symptom care to movement, creators, and menstrual wellness.
NUBEQA data at AUA 2026 sharpens Bayer’s mCSPC positioning against androgen receptor rivals
Bayer has stronger NUBEQA mCSPC data. The tougher test is whether clinicians view ARASEC as confirmatory or merely supportive.
What Bayer’s MRXperion 510(k) clearance means for high-field MRI workflow and contrast injection systems
FDA clears expanded capabilities for Bayer MRXperion MRI injector supporting scanners up to 7T. Discover what this means for imaging workflows and radiology systems.
Real-world data meets legal limits as Bayer targets ERLEADA claims in prostate cancer
Bayer’s lawsuit against Johnson and Johnson raises critical questions about real-world evidence and oncology marketing. Read what this means for drug claims.